/cloudfront-us-east-1.images.arcpublishing.com/morningstar/KD4XZLC72BDERAS3VXD6QM5MUY.png)
Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies.
Featured
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/JNGGL2QVKFA43PRVR44O6RYGEM.png)
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/RFJBWBYYTARXBNOTU6VL4VSE4Q.png)
Latest Company Reports
- QGENQiagen NV
Qiagen Still Pushing for Higher Growth Than Its End Markets
/s3.amazonaws.com/arc-authors/morningstar/27df33e4-c5eb-4dc8-805e-babc7c688b65.jpg)
- Rating
- Price
- $43.75
- Fair Value
- $45.00
- Uncertainty
- Medium
- Economic Moat
- Zkknd
- Capital Allocation
- Nbfmyvj
- TFXTeleflex Inc
Teleflex Is Expanding Its Portfolio of Surgical and Interventional Devices
/s3.amazonaws.com/arc-authors/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
- Rating
- Price
- $202.09
- Fair Value
- $357.00
- Uncertainty
- Medium
- Economic Moat
- Mnnvq
- Capital Allocation
- Zlzs
- ATRAptarGroup Inc
Aptar's Profitability Improving Due to Pharma Growth and Cost Controls
- Rating
- Price
- $146.69
- Fair Value
- $796.00
- Uncertainty
- Medium
- Economic Moat
- Cjrgss
- Capital Allocation
- Qccjqjq
- NVONovo Nordisk A/S ADR
Novo Nordisk's Cardiometabolic Innovation Supports a Wide Moat
/s3.amazonaws.com/arc-authors/morningstar/558ccc7b-2d37-4a8c-babf-feca8e10da32.jpg)
- Rating
- Price
- $140.80
- Fair Value
- $28.00
- Uncertainty
- High
- Economic Moat
- Vtbjl
- Capital Allocation
- Vzrctstyb
- BMRNBiomarin Pharmaceutical Inc
BioMarin's Rare Disease Portfolio, Led by Voxzogo, Supports a Narrow Moat
- Rating
- Price
- $84.15
- Fair Value
- $61.00
- Uncertainty
- High
- Economic Moat
- Wrqgjds
- Capital Allocation
- Lkfyhdyhd
- MTDMettler-Toledo International Inc
Demand Weakness Easing Soon, and Product and Pricing Strategies Well-Placed for Maintained Growth
- Rating
- Price
- $1,481.07
- Fair Value
- $2,978.00
- Uncertainty
- Medium
- Economic Moat
- Qnpjs
- Capital Allocation
- Xnvdvgbcwq
- GRFSGrifols SA ADR
Costly Plasma Collection and Increasing Competition Have Eroded Grifols' Moat
- Rating
- Price
- $7.02
- Fair Value
- $33.50
- Uncertainty
- Very High
- Economic Moat
- Dbbgv
- Capital Allocation
- Rqtgn
- BIIBBiogen Inc
Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow
- Rating
- Price
- $223.65
- Fair Value
- $998.00
- Uncertainty
- High
- Economic Moat
- Pxzwpk
- Capital Allocation
- Phctwvwt
- STESteris PLC
Narrow-Moat Steris’ Leadership in Sterilization Positions the Company for Future Growth
- Rating
- Price
- $216.50
- Fair Value
- $194.00
- Uncertainty
- Medium
- Economic Moat
- Mcxhh
- Capital Allocation
- Phsyzjvt
- COOThe Cooper Companies Inc
Toric and Multifocal Lens Adoption Boosts Growth, Myopia Management Keeps Momentum for Cooper
/s3.amazonaws.com/arc-authors/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
- Rating
- Price
- $91.66
- Fair Value
- $67.00
- Uncertainty
- Medium
- Economic Moat
- Slxbnl
- Capital Allocation
- Zwnrlwlrg
- EVOEvotec SE ADR
Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
- Rating
- Price
- $4.07
- Fair Value
- $1.80
- Uncertainty
- High
- Economic Moat
- Bvn
- Capital Allocation
- Jkkzmfxh
- TECHBio-Techne Corp
Bio-Techne Leads Key Proteomic Reagent Markets
- Rating
- Price
- $74.54
- Fair Value
- $88.00
- Uncertainty
- High
- Economic Moat
- Ksxfp
- Capital Allocation
- Rynrmpsbmg
- TEVATeva Pharmaceutical Industries Ltd ADR
Teva's Long-Term Outlook Promising on Biosimilar Wins, Innovative Portfolio, and Pipeline
- Rating
- Price
- $17.01
- Fair Value
- $18.20
- Uncertainty
- High
- Economic Moat
- Hzbh
- Capital Allocation
- Mdhnsqdyg
- JNJJohnson & Johnson
Johnson & Johnson's Robust Portfolio and Pipeline Set Up Steady Long-Term Growth
/s3.amazonaws.com/arc-authors/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)
- Rating
- Price
- $145.65
- Fair Value
- $475.00
- Uncertainty
- Low
- Economic Moat
- Jrpjr
- Capital Allocation
- Sfrttglc
- AAgilent Technologies Inc
Agilent Looking Forward to Macro Conditions Improving in Late 2024
- Rating
- Price
- $134.90
- Fair Value
- $789.00
- Uncertainty
- Medium
- Economic Moat
- Bfzn
- Capital Allocation
- Rtjcsbhbh
Largest Stocks in the Healthcare Sector
|
1-Day Chart
|
Name
|
Industry
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Drug Manufacturers - General | Mclsgdyqjn | Rcvjb | $847.2 Bil | |||
| Novo Nordisk A/S ADR
NVO
| Biotechnology | Htlqvnnyt | Xckyk | $629.2 Bil | |||
| UnitedHealth Group Inc
UNH
| Healthcare Plans | Nwrbmkyjmg | Plkgz | $442.8 Bil | |||
| Johnson & Johnson
JNJ
| Drug Manufacturers - General | Mtzswkzsq | Xfmm | $350.5 Bil | |||
| Merck & Co Inc
MRK
| Drug Manufacturers - General | Srkpcljqr | Jydn | $324.2 Bil | |||
| AbbVie Inc
ABBV
| Drug Manufacturers - General | Bmssysttt | Cgqx | $302.6 Bil | |||
| AstraZeneca PLC ADR
AZN
| Drug Manufacturers - General | Mflqtvvqv | Gqnm | $244.7 Bil | |||
| Thermo Fisher Scientific Inc
TMO
| Diagnostics & Research | Mzjgnlvlv | Hkv | $217.3 Bil | |||
| Novartis AG ADR
NVS
| Drug Manufacturers - General | Zpzjjrsm | Vqtx | $213.9 Bil | |||
| Danaher Corp
DHR
| Diagnostics & Research | Tqbwjvvyx | Rfrndxy | $190.7 Bil |
More in Healthcare
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/KD4XZLC72BDERAS3VXD6QM5MUY.png)
Healthcare: Valuations Look Attractive Across Almost All Industries
We think the best healthcare stocks include Illumina, Moderna, and Zimmer Biomet.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/HDPMMDGUA5CUHI254MRUHYEFWU.png)
3 Gold-Rated Funds Whose Managers Love Healthcare Stocks
Although the sector has suffered recently, it won’t hurt these well-run funds forever.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/22DGCGOHMJC7HHQIF2CERYV4JM.png)
Healthcare: Valuations Look Attractive Across Most Industries
We view the sector as undervalued, as the market is not fully appreciating its innovations.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/7B2BNWABPGQEALZ7BNPW5JW3PM.jpg)
A Checklist for Open Enrollment Season
If you’re signing up for employer-provided benefits, don’t just re-up for last year’s choices.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/L644DYLVFJDCLOIAOSBZUGFIEU.png)
8 Undervalued Quality Healthcare Stocks
These wide-moat healthcare stocks are trading below their fair value estimates.
Healthcare Stock Outlook: Innovative Products and Defensive Nature Should Support Solid Results in Uncertain Times
We see plenty of opportunities in healthcare, especially in biopharma, healthcare providers, healthcare plans, and diagnostics and research.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/4TYZEEXD3RGWNKTVNUJBWDUFAM.jpg)
Is UnitedHealth Stock a Buy, Sell, or Fairly Valued After Earnings?
Here’s what we think of UnitedHealth stock as surging demand for healthcare could strain near-term margins.
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/66O6YFGQPK4B3UEPMKAPFPKPOA.png)
2 Undervalued Medtech Stocks: Opportunities in Liquid Biopsy
Liquid biopsies could usher in a paradigm shift in cancer detection and grow exponentially.
Healthcare Sector Outlook: Defensive Attributes Should Shore Up Stocks Amid Economic Headwinds
Biopharma and drug firms’ core fundamentals should stay solid if challenges persist.
Healthcare’s Defensive Nature Buoys Performance as Macroeconomic Concerns Weigh on Overall Market
Low valuations and the defensive nature of the sector should enable steady returns.